Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41408-022-00768-5
Title: A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma
Authors: Chng, WJ 
Lonial, S
Morgan, GJ
Iida, S
Moreau, P
Kumar, SK
Twumasi-Ankrah, P
Villarreal, M
Dash, AB
Vorog, A
Zhang, X
Suryanarayan, K
Labotka, R
Dimopoulos, MA
Rajkumar, SV
Keywords: Humans
Multiple Myeloma
Lenalidomide
Dexamethasone
Boron Compounds
Chromosome Aberrations
Antineoplastic Combined Chemotherapy Protocols
Issue Date: 1-Dec-2023
Publisher: Springer Science and Business Media LLC
Citation: Chng, WJ, Lonial, S, Morgan, GJ, Iida, S, Moreau, P, Kumar, SK, Twumasi-Ankrah, P, Villarreal, M, Dash, AB, Vorog, A, Zhang, X, Suryanarayan, K, Labotka, R, Dimopoulos, MA, Rajkumar, SV (2023-12-01). A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma. Blood Cancer Journal 13 (1) : 14-. ScholarBank@NUS Repository. https://doi.org/10.1038/s41408-022-00768-5
Abstract: Some cytogenetic abnormalities (CAs) are associated with poorer prognosis in multiple myeloma (MM); proteasome inhibitors appear to benefit patients with high-risk CAs. We evaluated 2247 MM patients from the TOURMALINE-MM1/-MM2/-MM3/-MM4 trials to assess the PFS benefit of ixazomib plus lenalidomide-dexamethasone (Rd) vs placebo-Rd (TOURMALINE-MM1/-MM2) or ixazomib vs placebo (TOURMALINE-MM3/-MM4) in specific high-risk CAs. After a pooled median follow-up of 25.6 months, the hazard ratio (HR) for PFS with ixazomib- vs placebo-based therapy for high-risk patients was 0.74 (95% confidence interval [CI]: 0.59–0.93; median PFS [mPFS] 17.8 vs 13.2 months), and 0.70 (95% CI: 0.62–0.80; mPFS 26.3 vs 17.6 months) for complementary standard-risk patients. The HR for expanded high-risk patients was 0.75 (95% CI: 0.64–0.87; mPFS 18.1 vs 14.1 months), and 0.71 (95% CI: 0.59–0.85; mPFS 36.1 vs 21.4 months) for complementary standard-risk patients. The HR for PFS with ixazomib- vs placebo-based therapy was 0.68 in patients with t(4;14) (95% CI: 0.48–0.96; mPFS 22.4 vs 13.2 months), and 0.77 for patients with amp1q21 (95% CI: 0.63–0.93; mPFS 18.8 vs 14.5 months). A PFS benefit was demonstrated with ixazomib- vs placebo-based therapy regardless of cytogenetic status, with greatest benefit observed in patients with t(4;14) and amp1q21.
Source Title: Blood Cancer Journal
URI: https://scholarbank.nus.edu.sg/handle/10635/237477
ISSN: 2044-5385
DOI: 10.1038/s41408-022-00768-5
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therap.pdf1.06 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.